Free Trial

Equillium (EQ) Stock Forecast & Price Target

Equillium logo
$2.17 +0.10 (+4.83%)
Closing price 04:00 PM Eastern
Extended Trading
$2.12 -0.05 (-2.53%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Equillium - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
1
Buy
6

Based on 8 Wall Street analysts who have issued ratings for Equillium in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 1 has given a sell rating, 1 has given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for EQ.

Consensus Price Target

$7.67
253.30% Upside
According to the 8 analysts' twelve-month price targets for Equillium, the average price target is $7.67. The highest price target for EQ is $12.00, while the lowest price target for EQ is $5.00. The average price target represents a forecasted upside of 253.30% from the current price of $2.17.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for EQ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Equillium and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EQ Analyst Ratings Over Time

TypeCurrent Forecast
5/6/25 to 5/6/26
1 Month Ago
4/6/25 to 4/6/26
3 Months Ago
2/5/25 to 2/5/26
1 Year Ago
5/6/24 to 5/6/25
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
2 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.67$8.50$1.00$3.00
Forecasted Upside253.30% Upside322.89% Upside-32.43% Downside708.63% Upside
Consensus RatingModerate BuyHoldReduceModerate Buy

EQ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EQ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Equillium Stock vs. The Competition

TypeEquilliumMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.30
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside258.26% Upside978.20% Upside14.16% Upside
News Sentiment Rating
Positive News

See Recent EQ News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
4/23/2026
Oppenheimer Holdings, Inc. logo
Oppenheimer
3 of 5 stars
 Initiated CoverageOutperform$7.00+200.43%
4/17/2026
Roth Mkm logo
Roth Mkm
2 of 5 stars
Adam Walsh
Adam Walsh
Not Rated
Reiterated RatingBuy$12.00+495.53%
4/16/2026
William Woods
Not Rated
Initiated CoverageBuy$6.00+195.42%
4/13/2026Initiated CoverageStrong-Buy$6.00+252.94%
4/7/2026 Initiated CoverageOverweight$10.00+397.51%
3/27/2026 Reiterated RatingSell (D-)
2/26/2026 UpgradeHold
2/25/2026 Initiated CoverageBuy$5.00+160.42%
3/28/2025DowngradeStrong-BuyHold
8/19/2024 Reiterated RatingBuy$5.00 ➝ $5.00+536.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:30 PM ET.


EQ Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Equillium is $7.67, with a high forecast of $12.00 and a low forecast of $5.00.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last twelve months. There is currently 1 sell rating, 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EQ shares.

According to analysts, Equillium's stock has a predicted upside of 253.30% based on their 12-month stock forecasts.

Over the previous 90 days, Equillium's stock had 1 upgrade by analysts.

Equillium has been rated by research analysts at B. Riley Financial, Cantor Fitzgerald, Oppenheimer, Raymond James Financial, Roth Mkm, Stifel Nicolaus, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Equillium more than other "medical" companies. The consensus rating for Equillium is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how EQ compares to other companies.


This page (NASDAQ:EQ) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners